S262 Abstracts / Clinical Nutrition 37 (2018) S46eS314
weight. Thos study was carried out to identify clinical profile that could
influence on physicians’ decision to prescribe one or another kind of drugs.
Methods: The study was based on a retrospective design. Patients with
T2D poorly controlled who received a SGLT2i or a GLP1a as add-on therapy
were included. Patients with any contraindication for any of these drugs
were excluded as well as those who already received one of the other class.
Results: Epidemiological, clinical and anthropometric profile were ana-
lysed from 75 patients whorreceived GLP1a. Their characteristics were
compared to those T2D patients who received any SGLT2i. Patients who
received GLP1a were more likely to be women (74.7% vs 30.7%, p<0.001),
~ os, p¼0.021) and had higher body
younger (55.6±10.9 vs 59.4±10.9 an
mass index (BMI) (40.1±7.8 vs 33.7±6 kg/m2, p<0.001). Multivariate
analysis showed that age, BMI and female gender were independent
predictors for the prescription of GLP1a.
Conclusions: Gender, age and BMI are major and independent predictors
for physician’s choice to prescribe drugs to T2D patients with obesity.
Further investigations including patient’s preference and adverse effects
are needed to verify our observation.
Disclosure of interest: None declared.
MON-P315
GLP1 ANALOGUES IN OBESE PATIENTS WITH TYPE 2 DIABETES: A
WEIGHT-CENTERED ANALYSIS
 n-Blanco 2,*. 1 Internal Medicine Unit,
C. García-Figueras-Mateos 1, M. Cayo
Hospital SAS Jerez de la Frontera, Jerez de la Frontera, Spain;
2 presented increased time records in the TMT B. Phonemic fluency scores
Endocrinology and Nutrition Unit, Hospital SAS Jerez de la Frontera, Jerez
de la Frontera, Spain
* Corresponding author.
Rationale: The use of glucagon like peptide 1 analogues (GLP1a) for the
treatment of type 2 diabetes mellitus (T2DM) is growing. With a view to
identifying patient characteristics that could influence physicians’ pre-
scription of different GLP1a, we carried out this observational study in
routine clinical practice conditions. Outcomes after add-on these drugs
were described as well.
Methods: The study was based on a retrospective design. The following
variables were collected to identify potential influencing factors in patient
profile at baseline: gender, age, time of evolution of T2DM, body mass
index (BMI), HbA1c level and treatment with insulin. To measure out-
comes, changes in HbA1c and BMI at 6 months after add-on, were
assessed.
Results: 75 poorly controlled patients with T2DM who received any GLP1a
as add-on therapy were analysed. One-third of sample was constituited by
each one: exenatide-LAR [EL], dulaglutide [D] and liraglutide [L]). At
baseline, patients on D were older as compared to other GLP1a (D:
60.8 ± 10.8 vs EL: 51.8 ± 10 vs L: 54.2 ±10.2 years; p¼0.008). There was a
non-significant trend to prescribe EL in patients with higher BMI ([Kg/m2]:
EL: 41.8 ± 8.8 vs L: 40.7 ± 7.3 vs D: 37.8 ± 6.9; p ¼ 0.17) and D to patients
with higher level of HbA1c ([%]: D: 9.2 ± 1.4 vs EL: 8.7 ± 1.7 vs L: 8.5 ± 1.1;
p ¼ 0.23). No significant changes in HbA1c and BMI reductions were
detected. BMI reductions were also equivalent among groups.
Conclusions: According to the trends of use of GLP1a, we can conclude
that there is a nonsignificant perception of a higher HbA1c-lowering effect
and better security profile for D and a higher weight-lowering effect for EL
among physicians. Nevertheless, HbA1c and BMI reductions are equivalent
among different types of GLP1a in our routine clinical practice.
Disclosure of interest: None declared.
MON-P316
COGNITIVE FUNCTION IN OBESE SUBJECTS
M.Arnoriaga Rodríguez 1, *, G. Blasco 2, C. Coll 3, W. Ricart 1, J. Puig 2, J. Garre-
 -Torrent ndez-Real 1. 1 Department of
Olmo 4, J. Gich 3, L. Ramio a 3, J.M. Ferna
Diabetes, Endocrinology and Nutrition, Biomedical Research Institute
(IdIBGi), Dr. Josep Trueta University Hospital, CIBEROBN (CB06/03/010),
Instituto de Salud Carlos III (ISCIII), Spain; 2 Department of Radiology,
Biomedical Research Institute (IdIBGi), Spain; 3 Department of Neurology.
Descargado para Anonymous User (n/a) en Edifici Santa Caterina de ClinicalKey.es por Elsevier en septiembre 13, 2018.
Para uso personal exclusivamente. No se permiten otros usos sin autorización. Copyright ©2018. Elsevier Inc. Todos los derechos reservados.
Neuroimmunology and Multiple Sclerosis Unit. Neurodegeneration and
Neuroinflamation Group, Dr. Josep Trueta University Hospital, Biomedical
Research Institute (IdIBGi), Spain; 4 Research group on Ageing, Health and
Disability, Institut d'Assistencia Sanitaria, Girona, Spain
* Corresponding author.
Rationale: Cognitive impairment is increasingly recognized to be over-
represented among obese subjects. Our study aimed to evaluate cognitive
function in middle-age obese compared with non-obese subjects similar in
age, sex and menopause status.
Methods: A cross-sectional, case-control study that included 121 subjects
(27.2e66.6 years) was undertaken. Verbal learning and memory was
evaluated by California Verbal Learning Test (CVLT), working memory by
Digit Span (DS), executive function by Trail Making Test (TMT), inhibition
by Stroop Test (ST), verbal comprehension by Vocabulary and Similarities
(WAIS-III) and depression traits by Patient Health Questionnaire 9 (PHQ-
9). Student’s t-test, Mann-Whitney U test and multivariate linear regres-
sion analyses were used to compare the differences between groups.
Results: 65 obese and 56 non-obese individuals were studied. The differ-
ences in cognitive traits were more marked among women. Post-
menopausal obese women had lower scores in the CVLT Immediate Recall
test (p¼0.045) while premenopausal obese women had lower scores in the
CVLT Short Delayed Free and Cued Recall tests (p¼0.009). Decreased scores
in Forward DS (p¼0.001) and Total DS (p¼0.036) were also observed in
premenopausal women. Regarding executive functions, obese women
were lower among premenopausal obese women (p¼0.003). Obese
women showed reduced scores in the ST Color-Word test. All obese sub-
jects had also lower scores in the Vocabulary and PHQ-9 traits. Many of
these differences remained significant after adjusting for age and years of
education. No significant differences were observed in the rest of CVLT,
TMT A and Semantic fluency task.
Conclusions: Middle-aged obese subjects had impairments in the main
cognitive domains explored compared with non-obese subjects of similar
age. These results might have implications in education strategies and
cognitive training in obese subjects.
Disclosure of interest: M. Arnoriaga Rodríguez Grant/Research Support
from: This work was partially supported by research grant PI15/01934
from the Instituto de Salud Carlos III from Spain, G. Blasco: None declared,
C. Coll: None declared, W. Ricart: None declared, J. Puig: None declared, J.
Garre-Olmo: None declared, J. Gich: None declared, L. Ramio  -Torrent
a:
None declared, J. M. Fernandez-Real: None declared.
MON-P317
DIETARY FACTORS RELATED TO MUSCLE STRENGTH IN ELDERLY
PATIENTS WITH METABOLIC SYNDROME AND HIGH CARDIOVASCULAR
RISK
M. Ortiz 1, *, M. Torrego 1, A. Barabash 1, M.A. Rubio 1, A. Larrad 1, G.
Hernandez 1, C. Moreno 2, M. Gonza lez 3, R. Cabrera 4, P.
1 1
Matía . Endocrinology and Nutrition, Hospital Clínico San Carlos, Instituto
de Investigacion Sanitaria San Carlos (IdISSC), Spain; 2 Centro de Salud
Lucero, Spain; 3 Centro de Salud Guzman el Bueno, Spain; 4 Centro de Salud
Espronceda, Madrid, Spain
* Corresponding author.
Rationale: Muscle strength (Ms) is associated with sarcopenia, function,
and ultimately, with frailty. The objetive of this study is to describe dietary
factors -food groups (FG), nutrients (N) and energy (E)- related to Ms in a
sample of elderly patients with metabolic syndrome before starting a
nutritional intervention.
Methods: Observational cross-sectional survey. Handgrip strength
(Jamar® dynamometer in dominant member) and intake (food frequency
questionnaire, Preventive Medicine Dept., Universidad de Navarra) were
determined. Statistics: Bivariate correlation (Spearman) and multiple
linear regression (multivariate analysis for N/E).
Results: 124 patients (50.8% women, median age 64 years (IQR 61e69),
mean BMI 32.26 kg/m2 (IQR: 29.5e34.7). Age was negatively associated